EveryDose, the intelligent medication management platform for patients, care teams, and healthcare organizations, announced today that it has successfully completed its SOC 2 Type II examination and HIPAA compliance review for the fourth consecutive year.
The independent SOC 2 Type II assessment evaluates an organization’s controls over an extended period of time, confirming that systems and processes are not only designed appropriately, but also operate effectively on an ongoing basis. The HIPAA review affirms that EveryDose continues to meet the administrative, physical, and technical safeguards required to protect protected health information (PHI).
Together, these reports reinforce EveryDose’s long-standing commitment to security, privacy, and operational excellence as the platform supports mission-critical medication workflows across health systems, health plans, and life sciences organizations.
“Maintaining SOC 2 Type II and HIPAA certification for four consecutive years reflects our commitment to security and compliance,” said Andrew Hourani, Founder & CEO of EveryDose. “As we continue to expand our partnerships in the healthcare industry, safeguarding data remains our top priority. This milestone reinforces our dedication to providing a secure, trusted platform for medication management and patient engagement.”
EveryDose’s compliance with SOC 2 Type II and HIPAA provides reassurance to healthcare organizations that their data is protected through rigorous security protocols, continuous monitoring, and proactive risk management. This certification reflects the company’s broader mission to empower care teams and patients with innovative, data-driven medication solutions—without compromising security.
Looking Ahead
As EveryDose continues to expand its platform and introduce new AI-driven capabilities, the company remains committed to maintaining strong governance, security, and privacy practices that align with the evolving needs of healthcare organizations and regulators.